Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 0.68 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615313 | 0.84 | AVPR1A (0.70) | DRD2AVPR1A | |
| SCHEMBL6590608 | 0.82 | DRD2 (0.89) | DRD2HTR1A | |
| SCHEMBL3914302 | 0.81 | DRD2 (1.00) | DRD2HTR1A | |
| SCHEMBL6590682 | 0.77 | DRD2 (0.59) | DRD2AVPR1AHTR1A | |
| Oxalic Acid SCHEMBL6595691 | 0.76 | DRD2 (0.81) | DRD2HTR1A | |
| SCHEMBL6588695 | 0.76 | DRD2 (0.78) | DRD2 | |
| SCHEMBL6589929 | 0.75 | DRD2 (0.89) | DRD2HTR1A | |
| SCHEMBL3913948 | 0.73 | DRD2 (1.00) | DRD2HTR1A | |
| Oxalic Acid SCHEMBL6776342 | 0.73 | DRD2 (0.66) | DRD2HTR1A | |
| Oxalic Acid SCHEMBL6777204 | 0.72 | DRD2 (0.64) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1007523-B9 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2004-09-08 | — | — | EP | disclosed |
| US-6727263-B2 | SEROTONINE REUPTAKE INHIBITOR; ANTIDEPRESSANTS; SIDE EFFECT REDUCTION | H. LUNDBECK A/S (DK) | 2004-04-27 | — | — | US | disclosed |
| EP-1007523-B1 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2003-10-22 | — | — | EP | disclosed |
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-01-23 | — | — | US | disclosed |
| US-6476035-B1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | TPH1, HTR1A, HTR3A | DRD2 26/4885AVPR1A 149/4885HTR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.